Wide Ranks

INTS

Intensity Therapeutics, Inc.

2.79

Top Statistics
Market Cap 42 M Forward PE -2.36 Revenue Growth 0.00 %
Current Ratio 2.32 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 6 M Total Cash Per Share 0.4590 Total Debt 151000
Total Debt To Equity 2.83 Current Ratio 2.32 Book Value Per Share 0.9600
All Measures
Short Ratio 305.00 % Message Board Id finmb_225412349 Fax 203-557-3023
Shares Short Prior Month 30238 Return On Equity -1.47 City Shelton
Uuid 8f52e929-8b6e-361a-bf1e-4405bee2d3bf Previous Close 2.74 First Trade Date Epoch Utc 1 B
Book Value 0.9600 Total Debt 151000 Volume 4477
Price To Book 2.90 Fifty Two Week Low 2.38 Total Cash Per Share 0.4590
Shares Short Previous Month Date 1 B Target Median Price 13.50 Max Age 86400
Recommendation Mean 1.25 Sand P52 Week Change 0.3133 Target Mean Price 12.00
Net Income To Common -15075000 Short Percent Of Float 0.0048 Implied Shares Outstanding 15 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 23450
Average Volume10days 23450 Total Cash 6 M Next Fiscal Year End 1 B
Held Percent Insiders 0.4716 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.74 Target Low Price 5.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 3.35 Open 2.79
Free Cashflow 9 M State CT Dividend Yield 0.00 %
Return On Assets -0.7274 Time Zone Short Name EST Trailing Eps -1.07
Day Low 2.75 Address1 1 Enterprise Drive Shares Outstanding 15 M
Price Hint 4 Target High Price 16.00 Website https://www.intensitytherapeutics.com
52 Week Change 0.1375 Average Volume 14471 Forward Eps -1.18
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 197.40 %
Is_sp_500 False Regular Market Day High 2.79 Profit Margins 0.00 %
Debt To Equity 2.83 Fifty Two Week High 11.44 Day High 2.79
Shares Short 44277 Regular Market Open 2.79 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0032
Operating Cashflow -14645000 Currency USD Time Zone Full Name America/New_York
Market Cap 42 M Is_nasdaq_100 False Zip 06484-4779
Quote Type EQUITY Industry Biotechnology Long Name Intensity Therapeutics, Inc.
Regular Market Day Low 2.75 Held Percent Institutions 0.1249 Current Price 2.79
Address2 Suite 430 Financial Currency USD Current Ratio 2.32
Industry Disp Biotechnology Number Of Analyst Opinions 4 Country United States
Float Shares 6 M Two Hundred Day Average 4.21 Enterprise Value 37 M
Forward PE -2.36 Regular Market Volume 4477 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States.

Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.

The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.